PARP
61 articles
PARP Inhibitors for Pancreatic Cancer Maintenance Treatment
Dr. Kim Reiss Binder is leading a clinical trial of maintenance treatment with the PARP inhibitor rucaparib, for patients who carry the BRCA mutation.
A Potential Role for PARP Inhibitors in Pancreatic Cancer
Dr. Michael Pishvaian leads research into the possible role of PARP inhibitors in treating pancreatic cancer patients with certain genetic mutations.
Genetic Testing Leads Me to a PARP Inhibitor Trial
Harvey Parker had genetic testing as part of his initial pancreatic cancer treatment. The BRCA2 mutation led him to a PARP inhibitor clinical trial.
A PARP Inhibitor Approval for Pancreatic Cancer
PARP inhibitors, a type of targeted therapy, are being studied as treatment for pancreatic cancer in a number of clinical trials.
Comparing a Standard Chemotherapy With and Without a PARP Inhibitor
A clinical trial compares standard chemotherapy with and without the addition of a PARP inihibitor, for patients whose pancreatic cancer is spreading again.
Testing a PARP Inhibitor for Metastatic Pancreatic Cancer Patients with DNA Repair Mutations
Researchers are testing a PARP inhibitor that is effective for cancers in pancreatic cancer patients with DNA repair mutations.
PARP Inhibitor as Maintenance for Pancreatic Cancer Patients with BRCA1, BRCA2, or PALB2 Mutations
A new clinical trial tests a PARP inhibitor as maintenance treatment for pancreatic cancer patients with BRCA1/2 or PALB2 mutations.
Exploiting DNA Mutations For Pancreatic Cancer Treatment
Dr. James Cleary explains how the researchers at Dana-Farber are looking to make PARP inhibitors even more effective for pancreatic cancer patients.
New Study Aims to Reduce Recurrence Risk for Select Patients
Dr. Kim A. Reiss is leading a study of the PARP inhibitor olaparib to delay or prevent a recurrence of surgically removed pancreatic cancer.
ASCO Annual Conference: Highlights in Pancreatic Cancer Research
Dr. Allyson Ocean reviews some of the latest pancreatic cancer research results, including new treatments for some patients.
BRCA’s Role in Pancreatic Cancer Investigated
The relationship between BRCA and pancreatic cancer, and how that affects treatment, is the focus of clinical trials looking at PARP inhibitors.
A Maintenance Trial for Patients with BRCA or PALB2 Mutations
A clinical trial examines whether the PARP inhibitor rucaparib can work as a maintenance drug for pancreatic cancer patients with BRCA or PALB2 mutations.
Treating BRCA-Negative Pancreatic Cancer Patients with a Family Cancer History Similar to BRCA Carriers
A clinical trial looks at the effectiveness of a PARP inhibitor in BRCA-negative pancreatic cancer patients with a family history BRCA-type cancers.
Damage as a Way to Repair Pancreatic Cancer
Dr. Talia Golan takes a closer look at the damage caused by the BRCA1/2 mutations to find a way to treat pancreatic cancer.
Targeted Therapy for Cancers Carrying the PALB2 Mutation
Researchers are testing a type of targeted therapy called a PARP inhibitor for cancers carrying the PALB2 mutation.